Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text

Medicine, Endocrinology, Pharmacology +15

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Tina Vilsbøll, Thure Krarup, Carolyn F. Deacon et al. · Diabetes · 2001 · 884 citations · Full text

Medicine, Endocrinology, Nutrition +16

Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide¹

Carolyn F. Deacon, Michael A. Nauck, Juris J. Meier et al. · The Journal of Clinical Endocrinology & Metabolism · 2000 · 400 citations · Full text

Life Sciences, Biochemistry, Endocrinology +17

Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes

Juris J. Meier, Katrin Hücking, Jens J. Holst et al. · Diabetes · 2001 · 229 citations

Medicine, Endocrinology, Internal Medicine +9

Evidence that enteroglucagon (II) is identical with the <i>C</i>-terminal sequence (residues 33-69) of glicentin

Jens J. Holst · Biochemical Journal · 1982 · 177 citations · Full text

Life Sciences, Biochemistry, Enzymology +10